Emotional DisordersNCT07458100
The STEP-MIED Trial: Digital Stepped-Care for Emotional Disorders
A study testing Mindfulness Intervention for Emotional Distress in people with Emotional Disorders and Depressive Disorder, run by Peking University at 1 site in China.
Trial summary
The goal of this clinical trial is to evaluate the effectiveness and cost-effectiveness of a digital mindfulness-based intervention in adults (aged 18-65) diagnosed with emotional disorders like depression or anxiety. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Emotional Disorders, Depressive Disorder, Anxiety Disorders
- What is being tested?
- Mindfulness Intervention for Emotional Distress
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 464 participants
- Where
- 1 siteChina
- Study dates
- 23 Mar 2026to May 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age: 18-65 years.
- Diagnosed with an emotional disorder by a outpatient psychiatrist, including depressive disorders, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, agoraphobia, social anxiety disorder), obsessive-compulsive disorder, post-traumatic stress disorder, and eating disorders (e.g., anorexia nervosa, bulimia nervosa).
- Symptom severity meeting the threshold: PHQ-9 score ≥10 or GAD-7 score ≥8.
Who cannot join
- Current diagnosis of psychotic disorders or bipolar disorder.
- Current organic mental disorders, pervasive developmental disorders, severe cognitive impairment, or substance use disorders.
- Current suicide risk (PHQ-9 item 9 score >2).
- Antisocial personality disorder.
- Severe medical illnesses that may affect intervention participation or require recent hospitalization.
- Previous participation in a systematic 8-week mindfulness course.
- Inability to access the internet.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Peking University
Beijing
Dongyang Chen, 86-18810673387, psychen@stu.pku.edu.cn
About this study
Official title: Effectiveness and Cost-effectiveness of a Digital Stepped-care Mindfulness Intervention for Recovery From Emotional Disorders: a Multicentre Pragmatic Randomized Controlled Trial
The goal of this clinical trial is to evaluate the effectiveness and cost-effectiveness of a digital mindfulness-based intervention in adults (aged 18-65) diagnosed with emotional disorders like depression or anxiety. The main questions it aims to answer are:
- Does adding a digital mindfulness intervention to usual care help people recover from emotional disorders faster and more sustainably over two years?
- Is this combined approach more cost-effective than usual care alone? Researchers will compare the group receiving the digital mindfulness intervention plus their usual treatment to the group receiving only their usual treatment to see if the intervention leads to better long-term recovery and represents good value for money.
Read more
Participants in the intervention group will:
- Attend eight weekly 2-hour online group mindfulness sessions.
- Use a WeChat mini-program for 49 days of guided mindfulness exercises and daily tasks.
- Patients who have not achieved reliable recovery after group retraining voluntarily participate in individual UP\&MIED counseling.
- Complete regular questionnaires and interviews over two years to track their progress.
All participants will continue to receive their usual medical care from their doctors throughout the study.
Read the detailed description
The prevalence of emotional disorders remains high, with depression and anxiety disorders being the most common (Freeman, 2022; Huang et al., 2019). Although existing treatments can alleviate symptoms in the short term, emotional disorders often follow a chronic and recurrent course, making long-term recovery difficult for patients (Mulder, 2015) and resulting in a persistent and heavy socioeconomic burden (Amos et al., 2018; GBD, 2022). Furthermore, individuals with emotional disorders often exhibit significant diagnostic instability and high comorbidity rates, making single-diagnosis interventions inadequate for real-world treatment needs (Bullis et al., 2019). Consequently, developing intervention strategies applicable to high comorbidity and capable of delivering long-term recovery benefits represents an urgent requirement in current emotional disorder treatment.
Transdiagnostic interventions are considered a key approach to meeting this need (Barlow et al., 2020). Grounded in the shared etiology and common mechanisms underlying psychopathology, these interventions enable practitioners to address diverse disorders using a single set of methods. Previous meta-analyses indicate that transdiagnostic interventions, exemplified by Mindfulness-Based Interventions (MBIs), yield moderate improvements in depressive and anxiety symptoms (Cuijpers et al., 2023). Specifically, Mindfulness-Based Stress Reduction (MBSR) has demonstrated potential as an alternative to medication in treating anxiety disorders (Hoge et al., 2023). For preventing depressive relapse in recurrent depression patients, Mindfulness-Based Cognitive Therapy (MBCT) proved as effective as maintenance antidepressant medication (Kuyken et al., 2015). The "Mindfulness Intervention for Emotional Distress" (MIED) employed in this study is a transdiagnostic psychological intervention developed based on MBSR and the "Unified Protocol for Cross-Diagnostic Treatment of Emotional Disorders" (UP). This program proposes a transdiagnostic psychopathology diamond model for emotional disorders, identifying four core pathological mechanisms hindering recovery: low distress tolerance, cognitive inflexibility, excessive emotional behavior, and abnormal engaging in life (Liu, 2024). MIED targets these four mechanisms through mindfulness practices combined with intervention strategies from UP (e.g., cognitive reappraisal, interoceptive exposure). This improvement of underlying pathological mechanisms is considered crucial for facilitating patients' transition from short-term symptom relief to robust, long-term recovery.
At the same time, the application of digital technology and group formats in psychological interventions continues to expand, providing low-threshold, scalable pathways for integrating transdiagnostic mindfulness interventions into routine healthcare systems (Schaeuffele et al., 2024). The digital MIED program has demonstrated promising effects in improving emotional distress and accelerating symptom improvement in emotional disorders across preliminary short-term studies (Ju et al., 2022; Li et al., 2024; Li et al., 2025; Wang et al., 2024). The high-frequency interaction compensates for the lack of proactive intervention tools in current clinical care. However, the efficacy of transdiagnostic interventions in promoting long-term recovery remains under-validated. Most transdiagnostic interventions, including mindfulness-based approaches, have primarily focused on single diagnostic dimensions (Barlow et al., 2017) or non-clinical samples (Lindegaard et al., 2021) , and generally lack large-sample support and long-term follow-up (Cuijpers et al., 2023; Newby et al., 2015; Schaeuffele et al., 2024) , making it difficult to reflect the long-term benefits for individuals with emotional disorders within real-world clinical pathways. Furthermore, the potential cost-effectiveness of such interventions remains under-examined (Schaeuffele et al., 2024). Against the backdrop of prolonged course and high comorbidity in emotional disorders, these evidence gaps constrain the effective integration of cross-diagnostic mindfulness interventions within routine healthcare systems.
Beyond this, the current limited understanding of the mechanisms of action also constrains improvements in treatment outcomes (Kazdin, 2007). While numerous theories have proposed hypotheses regarding these mechanisms (Baer, 2003; Brown et al., 2007; Garland et al., 2015; Liu, 2024; Shapiro et al., 2006), research on the mechanisms underlying MBIs remains lacking in systematic validation when measured against the criteria for establishing psychological intervention mechanisms proposed by Kazdin (Kazdin, 2007, 2009). No variables have been found to satisfy most mechanism validity criteria, with particularly insufficient evidence meeting experimental manipulation, temporal priority, and consistency criteria. More rigorous, high-quality research is needed to examine MBI mechanisms.
To address these evidence gaps, we plan to conduct a large-scale, multicenter, pragmatic randomized controlled trial evaluating the long-term efficacy and cost-effectiveness of a transdiagnostic digital mindfulness intervention as an adjunct to treatment as usual (TAU). This study will also incorporate an examination of MBI mechanisms of action, aiming to facilitate further optimization of intervention protocols.
- Conditions
- Emotional Disorders, Depressive Disorder, Anxiety Disorders, Obsessive-Compulsive Disorder, Post-Traumatic Stress Disorder, PTSD, Eating Disorders
- Being tested
- Mindfulness Intervention for Emotional Distress
- Keywords
- Cost-effectiveness, Mindfulness, Recovery, randomized controlled trial, stepped-care, Emotional Disorders
- Medical subject headings
- Depressive Disorder, Anxiety Disorders, Obsessive-Compulsive Disorder, Combat Disorders, Feeding and Eating Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mindfulness Intervention for Emotional DistressBehavioural
Also called MIED
MIED is a psychological intervention program based on "Mindfulness-Based Stress Reduction" (MBSR) and the "Unified Protocol for Transdiagnostic Treatment of Emotional Disorders" (UP), proposed by one of our authors. It includes a psychological diamond model of emotional distress and core intervention strategies (Liu, 2024). This program, in the form of mental health education courses, is suitable for patients with emotional disorders such as anxiety and depression. It has shown good effects in alleviating emotional distress in a series of preliminary studies (Ju et al., 2022; Li et al., 2023; Li et al., 2025; Wang et al., 2024). In this study, the intervention mainly adopts a step-care model, dynamically adjusting the intensity of the intervention according to the patient's recovery progress. All intervention content revolves around the four core transdiagnostic mechanisms of the MIED psychological diamond model and their corresponding core intervention strategies.
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group | Experimental | Participants in the MIED group will receive an eight-week live, online group course, along with 49 days of self-guided iMIED practice delivered through a digital platform. After completing the program, participants will be offered three optional online group refresher sessions, scheduled 1, 3, and 6 months post-intervention. Some participants, based on the assessment of the group instructors, may be recommended for individual counseling sessions. After the intervention, the research team will provide participants with educational materials on medication management communication and encourage them to discuss long-term treatment plans with their attending psychiatrists, including the possibility of optimizing medication doses based on stable conditions . All medical decisions must be ultimately determined by the psychiatrist . At the same time, throughout the study, participants will go through all their treatments as usual. Receives: Behavioral: Mindfulness Intervention for Emotional Distress |
| TAU Group | No intervention | Participants in the treatment as usual (TAU) group will continue to receive routine clinical treatment for emotional disorders at their respective centers, including pharmacotherapy, psychoeducation, supportive interviews, and necessary psychosocial services . Medication types, doses, and adjustments are entirely determined by clinicians based on the patient's condition. To describe treatment exposure, we will collect treatment information from patients at baseline, post-intervention, and at 6, 12, 18, and 24 months follow-up. To avoid intervention contamination, the research team will not provide any mindfulness-related materials or training to the TAU group before the trial ends. Participants are also advised to avoid participating in other 8-week mindfulness courses . If participation is necessary, relevant information will be recorded and handled sensitively in the analysis. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to Reliable Recovery
According to the standard definition of the IAPT (Improving Access to Psychological Therapies) system (El Baou et al., 2023; Gyani et al., 2013), reliable recovery requires meeting both of the following conditions simultaneously: (1) Reliable improvement: a decrease in PHQ-9 score of ≥6 points, or a decrease in GAD-7 score of ≥4 points, compared to baseline; (2) Symptoms below clinical thresholds: PHQ-9 < 10 and GAD-7 < 8. Time to reliable recovery is defined as the time from randomization to the first point at which both of the above criteria are met.
Measured: at baseline (T0), at week 3(T1) and at week 5 (T2), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Secondary outcomes (11)
Time to relapse
Time to relapse is defined as the time from achieving reliable recovery to the point at which, at any follow-up assessment, either of the following criteria is met: a PHQ-9 score ≥ 10 or a GAD-7 score ≥ 8
Measured: at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Rate of reliable improvement
Reliable improvement is a decrease in PHQ-9 score of ≥6 points, or a decrease in GAD-7 score of ≥4 points, compared to baseline. The rate of reliable improvement was calculated at each assessment time point.
Measured: at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Rate of reliable recovery
Reliable recovery requires meeting both of the following conditions simultaneously: (1) Reliable improvement (2) Symptoms below clinical thresholds: PHQ-9 < 10 and GAD-7 < 8. The rate of reliable recovery was calculated at each assessment time point.
Measured: at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Deterioration rate
Deterioration is defined according to IAPT criteria as a clinically significant worsening from baseline, operationalized as: PHQ-9 increase ≥ 6 points, or GAD-7 increase ≥ 4 points. The rate of deterioration was calculated at each assessment time point.
Measured: at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Health related quality of life
Using the EQ-5D-5L to measure, obtain health utility index and its changes over time, for estimating quality-adjusted life years (QALYs).The EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) is a standardized measure of health-related quality of life. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 5-level scale ranging from 1 (no problems) to 5 (extreme problems), describing the respondent's health status on the day of assessment. In addition, the EQ-5D-5L includes a visual analogue scale (EQ-VAS), on which participants rate their overall health from 0 (the worst health you can imagine) to 100 (the best health you can imagine)
Measured: at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Cost-effectiveness
The Treatment Inventory of Costs in Patients with Psychiatric Disorders (TIC-P) is designed to systematically assess both the direct medical costs (e.g., outpatient visits, hospitalizations, medication expenses) and indirect productivity losses (e.g., absenteeism, reduced work efficiency) associated with psychiatric disorders in adults. It includes a combination of quantitative and qualitative items and collects data through self-report by patients to evaluate the economic burden related to mental illness. Structured with a multidimensional framework, the TIC-P covers the frequency of healthcare resource utilization, cost accounting, and the impact on social functioning, enabling a comprehensive estimation of the economic costs associated with mental health interventions. The "cost" part of cost-effectiveness is measures with TIC-P, whereas the "effectiveness" part is the 24 months rate of reliable recovery.
Measured: at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Cost-utility
Cost is measured with TIC-P ; utility - QALYs derived from the EQ-5D-5L conversion.
Measured: at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Severity of depressive symptoms
Depressive symptoms measured using PHQ-9, focusing on how depression change over time.
Measured: at baseline(T0), at week3(T1), at week5(T2), at post-intervention(T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention.
Severity of anxiety symptoms
Anxiety symptoms measured using GAD-7, focusing on how anxiety symptoms change over time.
Measured: at baseline (T0), at week 3 (T1), at week 5 (T2), at post-intervention (T3), and at 6 (T4), 12 (T5), 18 (T6), and 24 (T7) months after the intervention.
Severity of insomnia symptoms
Insomnia symptoms measured using ISI, focusing on how insomnia symptoms change over time.
Measured: at baseline (T0), at week 3(T1) and at week 5 (T2), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Severity of somatic symptoms
Somatic symptoms measured using SSS-8, focusing on how somatic symptoms change over time.
Measured: at baseline (T0), at week 3 (T1), at week 5 (T2), at post-intervention (T3), and at 6 (T4), 12 (T5), 18 (T6), and 24 (T7) months after the intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Mar 2026
- Study start23 Mar 2026
- Primary completionMay 2028 (estimated)
- Study completionMay 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Emotional DisordersStudies of the same condition, open and under way.
- More trials run by Peking UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study follows a 3-step sequential stepped care model supported by a continuous AI-assisted Q\&A service available throughout the study period. Step 1 (Weeks 1-8) involves an 8-week online group Mindfulness-Informed Emotional Distress (MIED) course (2h/weekly) led by certified instructors and a 49-day self-guided digital practice via a WeChat mini-program, followed by psychiatric medication management education; Step 2 (Months 1-6 post-intervention) is a maintenance phase providing three optional group booster sessions (1-2h) at months 1, 3, and 6 to consolidate mindfulness gains; Step 3 (Months 6-8 post-intervention) offers intensified individual UP \& MIED counseling (up to eight 50-minute sessions) for participants not achieving reliable recovery, focusing on personalized strategy integration and functional rehabilitation.
- Masking
- None (open label)
- Enrolment
- 464 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peking University
- Sponsor type
- University, hospital or other
- Collaborators
- WU'AN FIRST PEOPLE'S HOSPITAL, Xi'an Mental Health Center, The Second Hospital of Anhui Medical University, The Guangxi Zhuang Autonomous Region Brain Hospital, DONG GUAN SEVENTH PEOPLE'S HOSPITAL, Affiliated Mental Health Center of Kunming Medical University, People's Hospital of Zhengzhou University, The Affiliated Brain Hospital of Guangzhou Medical University, THE SIXTH AFFILIATED HOSPITAL OF GUANGDONG PHARMACEUTICAL UNIVERSITY, Xiamen Medical College Affiliated Xian Yue Hospital
- Responsible party
- Principal investigator, Xinghua Liu, Peking University
- Investigators
- Xinghua Liu, Principal investigator, School of Psychological and Cognitive Sciences,Peking University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07458100
- Sponsor's protocol ID
- E20250508
- Status last verified
- Apr 2026
- First submitted
- 2 Mar 2026
- Last updated
- 21 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Given that the data in this study involves sensitive mental health information of patients and ethical restrictions, this research plan does not share individual-level research data with the public. If there is a reasonable academic need, an application can be made through the corresponding author, and after evaluation by the research team and the ethics committee, a decision will be made on whether to provide the necessary data summary or analytical support.
Study at a glance
From the registry record, last updated by the sponsor on 21 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness and Cost-effectiveness of a Digital Stepped-care Mindfulness Intervention for Recovery From Emotional Disorders: a Multicentre Pragmatic Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07458100
- Acronym / sponsor ID
- E20250508
- Conditions
- Emotional Disorders, Depressive Disorder, Anxiety Disorders, Obsessive-Compulsive Disorder, Post-Traumatic Stress Disorder, PTSD, Eating Disorders
- Keywords
- Cost-effectiveness, Mindfulness, Recovery, randomized controlled trial, stepped-care, Emotional Disorders
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 464 participants (estimated)
- Lead sponsor
- Peking UniversityUniversity, hospital or other
- Collaborators
- WU'AN FIRST PEOPLE'S HOSPITAL, Xi'an Mental Health Center, The Second Hospital of Anhui Medical University, The Guangxi Zhuang Autonomous Region Brain Hospital, DONG GUAN SEVENTH PEOPLE'S HOSPITAL, Affiliated Mental Health Center of Kunming Medical University, People's Hospital of Zhengzhou University, The Affiliated Brain Hospital of Guangzhou Medical University, THE SIXTH AFFILIATED HOSPITAL OF GUANGDONG PHARMACEUTICAL UNIVERSITY, Xiamen Medical College Affiliated Xian Yue Hospital
- Study start
- 23 Mar 2026 (actual)
- Primary completion
- May 2028 (estimated)
- Study completion
- May 2028 (estimated)
- First posted
- 9 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the effectiveness and cost-effectiveness of a digital mindfulness-based intervention in adults (aged 18-65) diagnosed with emotional disorders like depression or anxiety. The main questions it aims to answer are:
- Does adding a digital mindfulness intervention to usual care help people recover from emotional disorders faster and more sustainably over two years?
- Is this combined approach more cost-effective than usual care alone? Researchers will compare the group receiving the digital mindfulness intervention plus their usual treatment to the group receiving only their usual treatment to see if the intervention leads to better long-term recovery and represents good value for money.
Participants in the intervention group will:
- Attend eight weekly 2-hour online group mindfulness sessions.
- Use a WeChat mini-program for 49 days of guided mindfulness exercises and daily tasks.
- Patients who have not achieved reliable recovery after group retraining voluntarily participate in individual UP\&MIED counseling.
- Complete regular questionnaires and interviews over two years to track their progress.
All participants will continue to receive their usual medical care from their doctors throughout the study.
Detailed description
The prevalence of emotional disorders remains high, with depression and anxiety disorders being the most common (Freeman, 2022; Huang et al., 2019). Although existing treatments can alleviate symptoms in the short term, emotional disorders often follow a chronic and recurrent course, making long-term recovery difficult for patients (Mulder, 2015) and resulting in a persistent and heavy socioeconomic burden (Amos et al., 2018; GBD, 2022). Furthermore, individuals with emotional disorders often exhibit significant diagnostic instability and high comorbidity rates, making single-diagnosis interventions inadequate for real-world treatment needs (Bullis et al., 2019). Consequently, developing intervention strategies applicable to high comorbidity and capable of delivering long-term recovery benefits represents an urgent requirement in current emotional disorder treatment.
Transdiagnostic interventions are considered a key approach to meeting this need (Barlow et al., 2020). Grounded in the shared etiology and common mechanisms underlying psychopathology, these interventions enable practitioners to address diverse disorders using a single set of methods. Previous meta-analyses indicate that transdiagnostic interventions, exemplified by Mindfulness-Based Interventions (MBIs), yield moderate improvements in depressive and anxiety symptoms (Cuijpers et al., 2023). Specifically, Mindfulness-Based Stress Reduction (MBSR) has demonstrated potential as an alternative to medication in treating anxiety disorders (Hoge et al., 2023). For preventing depressive relapse in recurrent depression patients, Mindfulness-Based Cognitive Therapy (MBCT) proved as effective as maintenance antidepressant medication (Kuyken et al., 2015). The "Mindfulness Intervention for Emotional Distress" (MIED) employed in this study is a transdiagnostic psychological intervention developed based on MBSR and the "Unified Protocol for Cross-Diagnostic Treatment of Emotional Disorders" (UP). This program proposes a transdiagnostic psychopathology diamond model for emotional disorders, identifying four core pathological mechanisms hindering recovery: low distress tolerance, cognitive inflexibility, excessive emotional behavior, and abnormal engaging in life (Liu, 2024). MIED targets these four mechanisms through mindfulness practices combined with intervention strategies from UP (e.g., cognitive reappraisal, interoceptive exposure). This improvement of underlying pathological mechanisms is considered crucial for facilitating patients' transition from short-term symptom relief to robust, long-term recovery.
At the same time, the application of digital technology and group formats in psychological interventions continues to expand, providing low-threshold, scalable pathways for integrating transdiagnostic mindfulness interventions into routine healthcare systems (Schaeuffele et al., 2024). The digital MIED program has demonstrated promising effects in improving emotional distress and accelerating symptom improvement in emotional disorders across preliminary short-term studies (Ju et al., 2022; Li et al., 2024; Li et al., 2025; Wang et al., 2024). The high-frequency interaction compensates for the lack of proactive intervention tools in current clinical care. However, the efficacy of transdiagnostic interventions in promoting long-term recovery remains under-validated. Most transdiagnostic interventions, including mindfulness-based approaches, have primarily focused on single diagnostic dimensions (Barlow et al., 2017) or non-clinical samples (Lindegaard et al., 2021) , and generally lack large-sample support and long-term follow-up (Cuijpers et al., 2023; Newby et al., 2015; Schaeuffele et al., 2024) , making it difficult to reflect the long-term benefits for individuals with emotional disorders within real-world clinical pathways. Furthermore, the potential cost-effectiveness of such interventions remains under-examined (Schaeuffele et al., 2024). Against the backdrop of prolonged course and high comorbidity in emotional disorders, these evidence gaps constrain the effective integration of cross-diagnostic mindfulness interventions within routine healthcare systems.
Beyond this, the current limited understanding of the mechanisms of action also constrains improvements in treatment outcomes (Kazdin, 2007). While numerous theories have proposed hypotheses regarding these mechanisms (Baer, 2003; Brown et al., 2007; Garland et al., 2015; Liu, 2024; Shapiro et al., 2006), research on the mechanisms underlying MBIs remains lacking in systematic validation when measured against the criteria for establishing psychological intervention mechanisms proposed by Kazdin (Kazdin, 2007, 2009). No variables have been found to satisfy most mechanism validity criteria, with particularly insufficient evidence meeting experimental manipulation, temporal priority, and consistency criteria. More rigorous, high-quality research is needed to examine MBI mechanisms.
To address these evidence gaps, we plan to conduct a large-scale, multicenter, pragmatic randomized controlled trial evaluating the long-term efficacy and cost-effectiveness of a transdiagnostic digital mindfulness intervention as an adjunct to treatment as usual (TAU). This study will also incorporate an examination of MBI mechanisms of action, aiming to facilitate further optimization of intervention protocols.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This study follows a 3-step sequential stepped care model supported by a continuous AI-assisted Q\&A service available throughout the study period. Step 1 (Weeks 1-8) involves an 8-week online group Mindfulness-Informed Emotional Distress (MIED) course (2h/weekly) led by certified instructors and a 49-day self-guided digital practice via a WeChat mini-program, followed by psychiatric medication management education; Step 2 (Months 1-6 post-intervention) is a maintenance phase providing three optional group booster sessions (1-2h) at months 1, 3, and 6 to consolidate mindfulness gains; Step 3 (Months 6-8 post-intervention) offers intensified individual UP \& MIED counseling (up to eight 50-minute sessions) for participants not achieving reliable recovery, focusing on personalized strategy integration and functional rehabilitation.
| Arm | Type | Receives |
|---|---|---|
| Intervention Group | Experimental | Behavioral: Mindfulness Intervention for Emotional DistressParticipants in the MIED group will receive an eight-week live, online group course, along with 49 days of self-guided iMIED practice delivered through a digital platform. After completing the program, participants will be offered three optional online group refresher sessions, scheduled 1, 3, and 6 months post-intervention. Some participants, based on the assessment of the group instructors, may be recommended for individual counseling sessions. After the intervention, the research team will provide participants with educational materials on medication management communication and encourage them to discuss long-term treatment plans with their attending psychiatrists, including the possibility of optimizing medication doses based on stable conditions . All medical decisions must be ultimately determined by the psychiatrist . At the same time, throughout the study, participants will go through all their treatments as usual. |
| TAU Group | No intervention | –Participants in the treatment as usual (TAU) group will continue to receive routine clinical treatment for emotional disorders at their respective centers, including pharmacotherapy, psychoeducation, supportive interviews, and necessary psychosocial services . Medication types, doses, and adjustments are entirely determined by clinicians based on the patient's condition. To describe treatment exposure, we will collect treatment information from patients at baseline, post-intervention, and at 6, 12, 18, and 24 months follow-up. To avoid intervention contamination, the research team will not provide any mindfulness-related materials or training to the TAU group before the trial ends. Participants are also advised to avoid participating in other 8-week mindfulness courses . If participation is necessary, relevant information will be recorded and handled sensitively in the analysis. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age: 18-65 years.
- Diagnosed with an emotional disorder by a outpatient psychiatrist, including depressive disorders, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, agoraphobia, social anxiety disorder), obsessive-compulsive disorder, post-traumatic stress disorder, and eating disorders (e.g., anorexia nervosa, bulimia nervosa).
- Symptom severity meeting the threshold: PHQ-9 score ≥10 or GAD-7 score ≥8.
Key exclusion criteria (7 listed)
- Current diagnosis of psychotic disorders or bipolar disorder.
- Current organic mental disorders, pervasive developmental disorders, severe cognitive impairment, or substance use disorders.
- Current suicide risk (PHQ-9 item 9 score >2).
- Antisocial personality disorder.
- Severe medical illnesses that may affect intervention participation or require recent hospitalization.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mindfulness Intervention for Emotional DistressAlso: MIEDMIED is a psychological intervention program based on "Mindfulness-Based Stress Reduction" (MBSR) and the "Unified Protocol for Transdiagnostic Treatment of Emotional Disorders" (UP), proposed by one of our authors. It includes a psychological diamond model of emotional distress and core intervention strategies (Liu, 2024). This program, in the form of mental health education courses, is suitable for patients with emotional disorders such as anxiety and depression. It has shown good effects in alleviating emotional distress in a series of preliminary studies (Ju et al., 2022; Li et al., 2023; Li et al., 2025; Wang et al., 2024). In this study, the intervention mainly adopts a step-care model, dynamically adjusting the intensity of the intervention according to the patient's recovery progress. All intervention content revolves around the four core transdiagnostic mechanisms of the MIED psychological diamond model and their corresponding core intervention strategies. | Behavioural | Intervention Group |
Primary outcome
Time to Reliable Recovery
Time frame: at baseline (T0), at week 3(T1) and at week 5 (T2), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
According to the standard definition of the IAPT (Improving Access to Psychological Therapies) system (El Baou et al., 2023; Gyani et al., 2013), reliable recovery requires meeting both of the following conditions simultaneously: (1) Reliable improvement: a decrease in PHQ-9 score of ≥6 points, or a decrease in GAD-7 score of ≥4 points, compared to baseline; (2) Symptoms below clinical thresholds: PHQ-9 < 10 and GAD-7 < 8. Time to reliable recovery is defined as the time from randomization to the first point at which both of the above criteria are met.
11 secondary outcomes
Time to relapse
Time frame: at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Rate of reliable improvement
Time frame: at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Rate of reliable recovery
Time frame: at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Deterioration rate
Time frame: at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Health related quality of life
Time frame: at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Cost-effectiveness
Time frame: at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Cost-utility
Time frame: at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Severity of depressive symptoms
Time frame: at baseline(T0), at week3(T1), at week5(T2), at post-intervention(T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention.
Severity of anxiety symptoms
Time frame: at baseline (T0), at week 3 (T1), at week 5 (T2), at post-intervention (T3), and at 6 (T4), 12 (T5), 18 (T6), and 24 (T7) months after the intervention.
Severity of insomnia symptoms
Time frame: at baseline (T0), at week 3(T1) and at week 5 (T2), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
Severity of somatic symptoms
Time frame: at baseline (T0), at week 3 (T1), at week 5 (T2), at post-intervention (T3), and at 6 (T4), 12 (T5), 18 (T6), and 24 (T7) months after the intervention.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Apr 2026.
- Individual participant dataSharing planned: No. Given that the data in this study involves sensitive mental health information of patients and ethical restrictions, this research plan does not share individual-level research data with the public. If there is a reasonable academic need, an application can be made through the corresponding author, and after evaluation by the research team and the ethics committee, a decision will be made on whether to provide the necessary data summary or analytical support.
Related trials for Emotional Disorders
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
RecruitingPhase 3
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
Recruiting
AI-assisted Home-based Intervention for ADHD Children
ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined Type
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Xinghua Liu principal investigator
School of Psychological and Cognitive Sciences,Peking University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mindfulness Intervention for Emotional Distress in people with Emotional Disorders and Depressive Disorder, run by Peking University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dongyang Chen (+8618810673387, psychen@stu.pku.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to Reliable Recovery (time frame: at baseline (T0), at week 3(T1) and at week 5 (T2), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2026.